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ABSTRACT 
Aims: To identify which factors predict the need for minor or major amputation in 
patients attending a multidisciplinary diabetic foot clinic. 
Methods: A retrospective analysis of patients who attended over a 27 month period 
were included. Patients had to have attended ≥3 consecutive consultant led clinic 
appointments within 6 months. Data was collected on HbA1c, clinic attendance, 
blood pressure, peripheral arterial disease (PAD), and co-morbidities. Patients were 
followed up for 1 year.  
Results: 165 patients met the inclusion criteria. 121 were male. 33 patients had 
amputations. There was  an association between poor glycaemic control at baseline 
and risk of amputation when adjusted for other factors, with those patients having 
HbA1c ≤58 at less risk of amputation with an odds of 0.14 (0.04 to 0.53)  of 
amputation(p=0.0036). Other statistically significant factors predictive of amputation 
were: missing clinic appointments (p=0.0079); a high Charlson index (p=0.03314); 
hypertension (p=0.0216). No previous revascularisation was protective against 
amputation (p=0.0035). However PAD was not seen to be statistically significant, 
although our results indicated a lower risk of amputation with no PAD. Overall, 
34.9% (n=58) of patients had good glycaemic control (HbA1c <58mmol/mol) at 
baseline & 81.3% (n=135) had improved their glycaemic control at their last follow up 
appointment. 
Conclusions: In this cohort poor glycaemic control, poor attendance, previous 
revascularisation & hypertension were associated with higher risk of amputation, with 
PAD showing a trend. Moreover, we demonstrated benefits in glycaemic control 
achieved by attending this DFC, which is likely to translate to longer term diabetes 
related health benefits. 
 
Keywords: 
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1.1 Introduction 
Diabetic foot ulceration (DFU) is a common complication of diabetes, with a life time 
risk of developing an ulcer between 10 and 25% [1]. Foot ulcers frequently lead to 
lower extremity amputation and are a marker of premature mortality [2].  Previous 
work has suggested that ulceration is associated with a 50 fold increased risk of 
subsequent hospitalisation, and a 150 fold increased risk of lower extremity 
amputation, compared to patients with diabetes and no ulceration [3]. Whilst infection 
of the wound is one of the leading causes of amputation, several other risk factors 
have been implicated in further increasing this risk. These include peripheral arterial 
disease, poor glycaemic control, and the presence of other diabetes related co-
morbidities [4-7]. 
 
It has been estimated that in England and Wales approximately 6000 people with 
diabetes have an amputation each year [8]. This equated to an overall expenditure 
on diabetes-related foot care and amputations of approximately £650million in 2010-
2011[8]. Lower extremity amputation remains a major problem globally, and is 
associated with significant morbidity and mortality [9;10]. In addition, quality of life is 
substantially reduced, due to the social and psychological consequences of 
amputation and ulceration [11].  
 
The UK National Institute for Health and Clinical Excellence (NICE) guidelines 
recommend using a multidisciplinary team (MDT) approach for patients with DFU 
[12]. This is because of the evidence base to show that the presence of 
multidisciplinary care with a well-designed team reduces rates of amputation and the 
length of hospital stay [12]. Few studies have examined what factors predict 
amputation, with most looking at prevention strategies [13]. Missing clinic 
appointments has been found to be associated with poor glycaemic control but to 
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date has not been investigated as an independent predictor of amputation [14]. 
Equally, whilst any patient undergoing amputation would be looked after in a 
secondary care environment, there are no data to evaluate outcomes according to 
different models of diabetes care – e.g. prior to amputation that the diabetes was 
managed exclusively in primary care – i.e. by the general practitioner and the 
practice nurse; or by the secondary care specialist diabetes team. However, it is 
accepted, that this may be because there are differences between these two groups 
with respect to severity, type and management processes for patients with diabetes, 
and local referral pathways. 
 
We aimed to use our cross sectional data to establish which factors were associated 
with an increased risk of minor or major amputation in patients attending the tertiary 
care diabetic foot clinic at our institution and determine their predictive value. We 
aimed to create a risk score that can be used in clinical practice to predict 
amputation. Such a model may help clinicians identify high-risk patients in order to 
provide appropriate treatment and prevent morbidity and mortality in a targeted 
fashion. Furthermore, we aimed to determine if there were any significant differences 
in outcomes of patients managed in primary versus secondary care. 
 
2.1 Subjects, Materials and Methods 
We conducted a retrospective case note analysis of patients referred to the MDT 
diabetic foot clinic at the Norfolk and Norwich University Hospital between 
September 2009 and December 2011. The sole inclusion criterion was that patients 
must have attended at least 3 consecutive appointments in a consultant led clinic in 
which a diabetes consultant was always present, accompanied by either a vascular 
or orthopaedic surgeon. These patients had more complex foot complications, e.g. 
osteomyelitis, Charcot neuroarthropathy, significant peripheral vascular disease, or 
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had additional needs that could not normally be managed by the podiatrists alone. 
The diabetes consultant was also involved in the review of diabetes medicine 
management and this included improvement of glycaemic control facilitated by 
dietary and pharmacological advice – the latter being dose titration of both oral and 
insulin based treatments, management of painful diabetes neuropathy, and where 
indicated, perioperative diabetes management. Those with consecutive 
appointments that were greater than 6 months apart were excluded because they 
were deemed to have had foot disease that was not significant enough to require 
intensive input from a senior clinician. Patients seen solely by the specialist 
podiatrists were also excluded since glycaemic management was not done in this 
group of patients as part of their foot care. In our institution, whilst the podiatrists are 
non-surgical, they have extensive diagnostic and clinical skills in the management of 
diabetic complications and have the responsibility for the ongoing management of 
the majority of the patients referred to the diabetic foot clinic. 
 
Baseline data was collected on previous revascularisation, co-morbidities, including 
hypertension and peripheral arterial disease (defined as the absence of both pulses 
in either foot) and was also reported as a Charlson Index score [15;16]. This is a 
previously validated scoring system that has been widely used to help predict 
mortality [17]. Hypertension was defined as a blood pressure of >140/80mmHg or 
being on an antihypertensive agent. In our clinic, whilst we routinely use a 10-gm 
Semmes Weinstein monofilament to check for the presence of neuropathy, to help 
identify the ‘at risk foot’, but in this dataset we did not include any measure of 
neuropathy. We documented whether the patients diabetes was managed by 
primary or secondary care at the time of referral. The number of times a patients 
attended a consultant led, clinic based care (months) and 3 consecutive clinic 
attendance rates (%) were recorded on our hospital appointment, patient 
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administration system. Baseline and subsequent information was collected from the 
clinic notes, the comprehensive letters generated from the specialist multidisciplinary 
foot clinics, and our electronic pathology database. The latter was used primarily for 
follow up because all HbA1c and other biochemistry and haematology results were 
reported here and any admissions for amputations were easily identifiable. Because 
of the retrospective nature of the study, the Norfolk and Norwich University Hospitals 
NHS Foundation Trust ethics committee classed this as a service improvement 
exercise and ethical approval was deemed to not be necessary.  
 
2.2 Statistical methods 
Amputation was modelled using a logistic regression model with forward stepwise 
model selection with a significance level of 5%. Unadjusted Odds ratios (ORs) with 
95% confidence intervals (CIs) were calculated to determine the effect size. Adjusted 
OR and 95% CI and P-values were from the likelihood ratio chi-square were reported 
based on the chosen logistic regression model. The SAS software (Version 9.3, 
2011,  SAS Institute Inc., Cary, NC, USA) was used to develop nomograms to 
estimate amputation probabilities and provide a visual aid for the model. The 
accuracy of the predictions was estimated by use of a bootstrap resampling 
technique as an independent dataset was not available. 
 
Based on these results, each factor was allocated a score to produce the nomogram 
(Figure 1) that we believe can be used to predict individual risk of amputation.  
 
3.1 Results 
447 cases were identified as being referred to the clinic between Jan 2009 and 
December 2011. Of the 447 case identified, 282 were excluded because they failed 
to attend 3 consecutive consultant led foot clinics (including 23 patients who were 
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lost to follow up), leaving 165 eligible for analysis. Patients were followed up for a 
minimum of 1 year i.e. until 31st December 2012. Amputation was the primary 
outcome measure (minor or major), with secondary measures including mortality and 
glycated haemoglobin (HbA1c); the latter was recorded at referral and at 3-6 monthly 
intervals. Data from the patients who died during the follow up period were included 
in the outcome measures. 
 
Of the 165 patients who were eligible for the study, 33 people (20%) underwent a 
total of 34 amputations. There were a total of 17 major amputations and 17 minor 
amputations, with 1 person having a minor and major amputation. As shown in Table 
1, there were significantly more males and the majority of patients had type 2 
diabetes mellitus. Table 2 shows the multivariable analysis highlighting factors that 
were independently associated with amputation. These were less than 100% 
attendance for 3 consultant led consecutive clinics, poor glycaemic control and 
hypertension. Patients who had undergone previous revascularisation or a low co-
morbid status had significantly lower rates of amputation. Peripheral arterial disease 
(PAD) showed a strong trend towards increased risk of amputation but did not 
achieve statistical significance (p=0.0594). 
 
Table 3 shows how patients who had their diabetes managed in primary care had 
statistically significantly lower glycated haemoglobin (HbA1c) at baseline (p<0.05). 
They also had lower rates of total amputations than those whose diabetes was 
managed in secondary care. However, this did not achieve statistical significance. 
The reduction in HbA1c for the whole cohort was 2.2mmol/mol (95%CI -0.4-4.8). For 
those people looked after initially exclusively in primary care, the mean decrease in 
HbA1c was 1.4mmol/mol (-2.8 to 5.7), and for secondary care the mean decrease 
was 2.6mmol/mol (0.7 to 5.9) (p=0.35). For those who did not undergo amputation 
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the mean decrease was 1.8mmol/mol (-1.0 to 4.6), and for those who had an 
amputation the decrease was 3.6mmol/mol (-3.1 to 10.3). Overall, 34.9% (n=58) of 
patients in this cohort had good glycaemic control (HbA1c <7.5% (58mmol/mol)), at 
baseline and 81.3% (n=107) had an improved glycaemic control at their last follow 
up appointment. Mortality rates between those patients whose diabetes was 
managed in primary or secondary care was not different.  
 
 
4.1 Discussion 
In this study we have found that poor glycaemic control, missing clinic appointments 
and hypertension were associated with increased risk of major and minor 
amputation. Previous revascularisation and low co-morbid status were associated 
with a lower risk of amputation. Figure 1 shows a nomogram derived from this data 
that acts as a basis for a predictive model for the risk for amputation.  
 
A recent multicentre prospective study looked at factors predictive of lower-extremity 
amputation in patients with an infected diabetic foot ulcer using patients from the 
Eurodiale cohort [7]. Those authors developed a risk score for predicting amputation 
incorporating the following: peri-wound oedema, foul smell, (non) purulent exudate, 
deep ulcer, positive probe-to-bone test, pretibial oedema, fever and elevated CRP. In 
addition, a number of classification systems to predict lower extremity amputation 
have been developed but currently lack the evidence base and are not deemed to be 
ready for widespread clinical application [18]. Most of the classification systems 
investigated clinical factors attributed to the foot and limb. To date, only one study 
has used a combination of additional patient factors in conjunction with wound/limb 
related factors to produce a more complete predictive model of amputation risk [19]. 
However, the authors studied patients with concomitant infection and investigated 
some factors not included in our cohort and vice versa. In addition, they limited 
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themselves to hospitalised patients, who represent a small fraction of the total 
number of patients seen in a clinic. The lower extremity amputation risk score the 
authors produced consisted of additional factors such as male gender, albumin 
<2.8g/dL, white blood cell count >11x109/L. The present study provides support for 
some of the factors already identified by Lipsky et al, but our model also identifies 
additional factors that may need to be considered – including those pertinent to the 
outpatient population. 
 
The improvement in glycaemic control we observed in 81.3% of the whole cohort is 
extremely encouraging, because poor glycaemic control has been showed to be a 
significant predictor of ulcer recurrence, in addition to contributing to the 
development of other micro and macrovascular complications [6;20].  
 
Poor clinic attendance has been shown to be a major factor in the development of 
many diabetes related complications, such as retinopathy [21]. Our data are 
consistent with this, and from the work from the North West Diabetes Foot Care 
Study which looked at the risk of developing new ulcers. They showed that the risk 
was increased if patients had previously not attended podiatry appointments, foot 
deformity, and evidence of peripheral neuropathy or PAD [22]. However, other work 
has suggested that poor clinic attendance is not a factor when considering the risk of 
developing of diabetes related foot disease [23]. Attendance is an important factor, 
but clearly, this would be removed from any prediction model. 
 
The majority of work around predicting amputation risk has been based on wound 
related factors, e.g. depth, infection or ischaemia [18]. The main strength of our 
study is that it used factors that have previously been overlooked to predict 
amputation risk.  
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We do acknowledge that our study has some limitations. We had a relatively small 
sample size, with only 165 eligible cases including 33 amputees. In order to 
strengthen our data, we plan on extending our collection period to 5 years. Larger, 
prospective studies will also be needed to validate these findings. It is worth noting 
that these patients were taken from a single centre in Norfolk, where 90% of the 
population are white British [24].  As a result, these results may not be generalisable 
to the wider population. By performing a sub-group analysis in patients from both 
primary and secondary care we have improved the external validity of our results 
although they do remain skewed towards those with more complex disease 
managed in secondary care. Another weakness of our study is the retrospective 
design in which we were reliant on accurate documentation, thereby increasing the 
possibility of information bias. Equally, the lack of randomisation increases the 
selection bias. In addition, we chose to only analyse patients seen in a consultant 
clinic at least 3 times, who, almost by definition had the most complex foot disease 
or were the most challenging patients. Through adjusting for the other variables we 
have attempted to minimise the effect of confounders, but some may remain. A 
possible barrier to implementing this model on a wider scale is the need for 
equipment to measure HbA1c. However, given the routine use of HbA1c to monitor 
glycaemic control in the management of diabetes mellitus this is unlikely to be a 
problem in clinical practice. We did not add infection to our list of potential risk 
factors, because this has already been shown to be strongly predictive of amputation 
[3]. We did not include a measure of neuropathy in our prediction model. Whilst the 
main reason for this was that we wished for the scoring system to be used in low 
resource environments, we also felt that because of the ongoing argument of ‘how is 
neuropathy diagnosed?’ [25], that this would lead to a greater generalisability of the 
findings without incurring controversy. 
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In conclusion, a cohort of patients attending our specialist MDT foot clinic, missing 
clinic appointments, hypertension and poor glycaemic control at baseline were 
associated with higher risk of amputation, with PAD showing a strong trend as well. 
Low co-morbid status and previous revascularisation were protective. Moreover, this 
case-note analysis demonstrated benefits in glycaemic control achieved by attending 
foot clinic, which is likely to translate to longer term diabetes related health benefits. 
We have used these results to develop a predictive model for amputation risk, 
although this needs to be validated with prospective studies done in different 
populations and a larger sample size. 
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Legends to Figures and Tables 
 
Table 1: Baseline characteristics of patients  
 
Table 2: Factors associated with amputation in patients attending the 
multidisciplinary foot clinic  
 
Table 3: Differences between patients managed in primary versus secondary care 
prior to referral 
 
Figure 1: Nomogram derived from the data in the Tables that acts as a basis for a 
predictive model for the risk for amputation. 
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Table 1 
Gender (M : F)  121 : 44 
Type of Diabetes Mellitus T1DM:T2DM  31 : 134 
 ANY AMPUTATION  
Amputation? YES NO TOTAL 
Number of patients (%) 33 (20) 132 (80) 165 
Age < 50 9 (32.1) 19 (67.9) 28 (16.9) 
50-54 4 (28.6) 10 (71.4) 14 (8.4) 
55-64 4 (13.8) 25 (86.2) 29 (17.5) 
65-74 8 (17.4) 38 (82.6) 46 (27.7) 
≥ 75 8 (16.3) 41 (83.7) 49 (29.5) 
HbA1c at baseline ≤7.5% : >7.5% 
(≤58 : >58 mmol/mol)  
8 : 25 
 
50 : 82 
 
 
Peripheral arterial disease n (%) 14 (29.2) 34 (70.8)  
Hypertension n (%)  32 (24.4) 99 (75.6)  
Previous revascularisation n (%) 6 (60) 4 (40)  
Charlson 
index 
≤ 5 7 62  
6 13 32  
≥ 7 13 39  
Renal 
function  
n (%) 
Normal (CKD 1)  7 (21.2) 26 (78.8)  
Mildly reduced (CKD 2-3) 16 (23.9) 51 (76.1)  
Moderate and Severe 
(CKD 4-5) 
4 (26.7) 11 (73.3)  
Duration 
of clinic 
care  
(months) 
< 3 7 13  
3 – 6 7 20  
6 – 12 4 31  
12 – 18 5 21  
> 18 10 47  
Table 2  
 
  Amputations (n=33)     
  No % Yes % Total 
Reference 
value 
Unadjusted 
OR (95%CI) 
Adjusted 
OR (95%CI) 
Adjusted 
p value* 
Attendance rate           
 <100% 54 72.0 21 28 75 
100 
2.56 
(1.16-5.64) 
3.84 
(1.54-9.52) 
0.0038 
 100% 79 86.8 12 13.2 91 
Charlson Index           
 <5 62 89.9 7 10.1 69 
>5 
0.31 
(0.13-0.76) 
0.32 
(0.11-0.91) 
0.0331 
 >5 71 74 25 26 96 
Hypertension           
 No 33 97.1 1 2.9 34 
Yes 
0.09 
(0.01-0.71) 
0.078 
(0.01-0.69) 
0.0216 
 Yes 99 75.6 32 24.4 131 
Peripheral 
Arterial Disease 
          
 No 98 83.8 19 16.2 117 
Yes 
0.47 
(0.21-1.04) 
0.89 
(0.35-2.30) 
0.811 
 Yes 34 70.8 14 29.2 48 
HbA1c 
(mmol/mol) 
          
 <58 50 86.2 8 13.8 58 
>58 
0.52 
(0.22-1.25) 
02.96 
(0.10-0.84) 
0.0227 
 >58 82 76.6 25 23.4 107 
Previous 
revascularisation 
          
 No 128 82.6 27 17.4 155 
Yes 
0.14 
(0.04-0.53) 
0.08 
(0.02-0.44) 
0.0035 
 Yes 4 40 6 60 10 
Type of diabetes           
 Type 1 21 15.9 10 30.3 31 
Type 2 
2.3 
(0.96-5.52 
3.15 
(1.10-9.0) 
0.0321 
 Type 2 111 84.1 23 69.7 134 
 
 *Likelihood Ratio Chi-square  
1 
 
Table 3 
 
 
 
Primary care Secondary care Chi-square p-value 
Total number 62 104  
HbA1c at baseline 
(mmol/mol, %) 
≤7.5%(≤58) 50% 26.2% 
<0.05 
>7.5%(>58) 50% 73.8% 
HbA1c lower at last follow up (%) 77.4% (n=48) 83.7% (n=87) 0.319 
 
Amputations 
 
Major  4 (6.5%) 13 (12.6%) 0.207 
Minor  7 (11.3%) 10 (9.7%) 0.746 
All 11 (17.7%) 23 (22.1%) 0.350 
Death 13 (21.3%) 19 (18.6%) 0.676 
 
 
